Cancer Vaccine Breakthrough for Lynch Syndrome Patients

Kilder

• Nature: Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial - Nature
• Nature: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial - Nature
• Nature: Single-cell atlas of the developing Down syndrome brain cortex - Nature
• Fiercebiotech: Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program - Fierce Biotech
• Biopharmadive: On biotech’s biggest stage, renewed excitement gets a stress test - BioPharma Dive
• Nature: Soft implantation of flexible electronic hairs via tip-focused radiofrequency perforation for in-tissue electrophysiology - Nature

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.